BAM
IMVT icon

Blueshift Asset Management’s Immunovant IMVT Stock Holding History

Blueshift Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Buy
+6,137
New +$187K 0.05% 449
2021
Q4 		– Sell
-13,393
Closed -$116K – 1029
2021
Q3 		$116K Buy
+13,393
New +$121K 0.01% 954
2021
Q1 		– Sell
-5,296
Closed -$245K – 952
2020
Q4 		$245K Buy
+5,296
New +$245K 0.03% 572

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blueshift Asset Management's IMVT Position: Q2 2026 in Review

Blueshift Asset Management opened a new position in Immunovant (IMVT) in Q2 2026: 6,137 shares worth $236K. The stake represents 0.05% of the portfolio and ranks #449 among its holdings. This is a return to the name: Blueshift Asset Management previously reported a position in IMVT as recently as Q3 2021.

Blueshift Asset Management first reported a position in IMVT in Q4 2020 and has held it in 3 quarters since. The position peaked at $245K in Q4 2020. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Blueshift Asset Management held 6,137 shares of Immunovant worth $236K as of Q2 2026.
  • Immunovant was a new Blueshift Asset Management position in Q2 2026.
  • Immunovant made up 0.05% of Blueshift Asset Management's portfolio in Q2 2026, its #449 holding.
  • Blueshift Asset Management first reported a position in Immunovant in Q4 2020 and has held it in 3 quarters since.
  • Blueshift Asset Management's Immunovant position peaked at $245K in Q4 2020.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Blueshift Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.